GRI BIO INC (GRI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.80-10.00%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Control operating losses near negative $2.0 million per quarter: metric not reported.
GRI Bio has about $11 million cash to fund operations into 2027. The company is advancing microbiome therapies for serious diseases. It beat earnings recently, showing some progress. If it controls losses better, it could improve its outlook.
GRI Bio keeps losing money and burning more cash. It faces Nasdaq delisting risks. The company has no revenue yet and negative earnings expected. These problems could worsen and hurt the stock.
The stock trades about 56% below our fair value of $4.24. The market expects negative growth and continued losses. We see some chance of recovery but risks remain high.
Breaks if: cash falls below $11 million before mid-2027
Ensure cash resources support planned operating expenses and capital expenditures into early to mid-2027.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as GRI is focused on advancing its clinical programs while navigating a challenging financial landscape. The current thesis is mixed, reflecting both potential and risks in the near term.
The market appears to price GRI as relatively inexpensive compared to its peers, but with low confidence in its valuation model. There is an expectation of fragility due to the company's loss-making status and elevated risk factors.
Fundamentally, GRI's trajectory may show mixed results as management works to advance its clinical programs while managing cash burn. The recent improvement in net loss suggests some progress, but the elevated probability of an earnings miss adds uncertainty.
The thesis hinges on several factors, including the company's ability to maintain guidance, the performance of sector bellwethers, and the overall economic environment affecting healthcare stocks. Any cuts to guidance or worsening economic indicators could lead to unfavorable outcomes.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
Yes, our read has strengthened. Positive Phase 2a data supports GRI-0621's clinical development for IPF. This advancement reinforces the company's outlook and potential in the market.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 3 of last 3 quarters. Cash increased from approximately $8.2 million at 2025-Q4 to $11.0 million at 2026-Q1, supporting planned operations into Q2 2027. Management consistently affirms sufficient cash runway, indicating delivery on this priority.
“Management reiterates cash runway into second quarter of 2027 with $11.0 million cash balance.”
“Cash and cash equivalents totaled approximately $11.0 million as of March 31, 2026, supporting operations into Q2 2027.”
“Company believes existing cash sufficient to fund operating expenses and capital expenditures into Q1 2027.”
Breaks if: losses worsen beyond -$2.0 million per quarter
Control operating losses and reduce cash burn through expense management and clinical trial completion.
Stated as a priority in 3 of last 3 quarters. Net loss improved from $3.4 million in 2025-Q3 to $1.6 million in 2026-Q2, reflecting reduced R&D expenses after Phase 2a trial completion. Cash burn remains negative but stable, indicating limited progress in further reduction.
“Net loss approximately $1.6 million for the quarter ended June 30, 2026.”
“Net loss approximately $2.0 million, down from $3.0 million in prior year period.”
“Operating loss was approximately $2.7 million for the quarter.”
Breaks if: revenue fails to reach $11 million by mid-2027
In the next 1 to 3 years, GRI's performance will depend on its clinical advancements and external market conditions. Not investment advice.